CASI Pharmaceuticals Inc (NASDAQ: CASI) has reported E.P.S. of $-0.45 for its fourth fiscal quarter (ending December 31) versus $-1.44 for the same period a year ago. For the latest four quarters through December 31, E.P.S. were $-2.02 versus $-3.01 for the same period a year ago.
Recent Price Action
CASI Pharmaceuticals Inc (NASDAQ: CASI) stock enjoyed a major increase of 20.3% on 3/28/24. The shares closed at $3.61. However, this advance was accompanied by unusually low trading volume at 51% of normal. The stock has been exceptionally strong relative to the market over the last nine months and has risen 16.1% during the last week.
Current PriceTarget Research Rating
CASI’s future returns on capital are forecasted to be below the cost of capital. Accordingly, the company is expected to continue to be a modest Value Eraser.
CASI Pharmaceuticals has a current Value Trend Rating of B (Positive). This rating combines very contradictory signals from two proprietary PTR measures of a stock’s attractiveness. CASI Pharmaceuticals has a slightly negative Appreciation Score of 35 but a very high Power Rating of 98, resulting in the Positive Value Trend Rating.
Rating Review
In light of this new information and very positive price change we are reviewing our current Overall Rating of B. This review will be completed in the next several days.
Be the first to comment